Zymeworks Inc. Delivers Fourth Quarter 2025 Financial Results and Strategic Progress

Vancouver, British Columbia — Zymeworks Inc., a clinical-stage biotechnology company focused on developing and commercializing novel biotherapeutics, released its financial results for the fourth quarter and full year ended December 31, 2025. The company also discussed its corporate strategy and expectations for future milestones during its quarterly earnings call and related investor presentation.

Quarterly Fiscal Performance

Zymeworks reported a continuation of its ongoing transformation with unaudited financial results for Q4 2025 demonstrating significant changes compared to prior year figures:

• Revenue for the fourth quarter was approximately $2.52 million, a steep year-over-year decline compared to the same period last year.
• Earnings per Share (EPS) stood at a loss of $0.55 per share on a GAAP basis, missing analysts’ expectations.
• Net Loss widened to roughly $41.2 million in Q4, compared with about $23.5 million in Q4 2024.
• Total Revenue for Full Year 2025 was $106.0 million, representing a 39% increase over 2024’s annual figure.
• Cash Position remained strong with approximately $270.6 million in cash, cash equivalents and marketable securities as of Dec. 31, 2025.

The company also highlighted differences in operating expenses and other income items, with reductions in R&D and G&A spending compared to the previous year, reflecting tighter cost discipline.

Business Highlights and Pipeline Progress

Alongside financial results, Zymeworks provided key corporate and operational updates highlighting important developments:

Product Development and Regulatory Milestones

Zymeworks noted progress in the commercial and regulatory path for Ziihera® (zanidatamab-hrii), an investigational therapy being developed in collaboration with partners. The supplemental biologics license application (sBLA) for first-line treatment of HER2-positive gastroesophageal adenocarcinoma (GEA) is anticipated to be completed by its partner in the first quarter of 2026 in the U.S., with potential launch projected in the second half of 2026.

If regulatory approvals are achieved globally in key markets including the U.S., Europe, Japan and China, Zymeworks expects to earn up to approximately $440 million in milestone payments tied to these achievements.

Strategic Corporate Developments

In order to support its long-term strategy and shareholder value creation, the company announced a $250 million non-recourse royalty-backed note financing from Royalty Pharma. This financing is intended to supplement Zymeworks’ cash runway and support share repurchases and possibly future strategic acquisitions, providing non-dilutive capital.

Zymeworks also reported that as of early March 2026, it has already utilized approximately $62.5 million in share repurchases under its existing authorized buyback program.

Pipeline Updates and Partner Progress

The company highlighted additional clinical progress through its partners, including updated data presentations for pasritamig in prostate cancer at the ASCO-GU meeting in February 2026, reported by Johnson & Johnson Innovative Medicine (J&J).

Management Commentary and Strategic Outlook

Kenneth Galbraith, Chair, CEO and interim CFO of Zymeworks, emphasized the company’s shift toward disciplined capital allocation and a focus on sustainable, recurring revenue streams through royalties rather than traditional biopharmaceutical commercialization alone.

According to management remarks, Zymeworks intends to leverage its cash position to further both internal R&D capabilities and investments in externally sourced assets that align with its strategic focus. Emphasis remains on delivering long-term value to shareholders through both organic growth and selective strategic transactions.

Analyst Perspectives and Market Reaction

Following the earnings release, analysts noted mixed reactions due to the combination of sharp quarterly revenue decline and high potential earnings tied to regulatory milestones. Some investors view the significant drop in quarterly revenues as a short-term challenge, while others focus on the long-term promise of pipeline progress and strategic financial moves.

The company’s stock price reflected the market’s nuanced interpretation of these results, with some analysts maintaining optimistic long-term price targets based on upcoming catalyst events, including potential regulatory approvals and milestone earnings.

Looking Ahead

Zymeworks remains focused on several key objectives as it moves into 2026:

1. Advancing regulatory submissions for Ziihera® and preparing for potential global launches.
2. Executing shareholder friendly capital allocation strategies while preserving financial flexibility.
3. Continuing to support partner-led clinical programs and data dissemination.

Management expects the combination of milestone earnings, royalty streams and pipeline development to improve both near-term financial performance and long-term growth prospects for the company and its shareholders.

#Zymeworks #ZYME #BiotechEarnings #Ziihera #SlimScan #GrowthStocks #CANSLIM